Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna T...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

burbs88 Apr. 25 at 9:57 AM

$NTLA

0 · Reply

leon_dedrick Apr. 25 at 9:48 AM

$NTLA If these guys are successful Monday I think it will be more bullish for $EDIT thank any other company Why Just ask Google what licenses they hold!!!!

0 · Reply

burbs88 Apr. 25 at 9:47 AM

$CRSP $NTLA Biggest day in space Monday since Casgevy approval. The selling was just typical hedging ahead of super high risk event.

0 · Reply

janetgonzales54 Apr. 25 at 9:00 AM

$NTLA

0 · Reply

janetgonzales54 Apr. 25 at 8:36 AM

$NTLA

0 · Reply

Shirzo Apr. 25 at 8:33 AM

$CRSP move to $NTLA

0 · Reply

TKkamen Apr. 25 at 8:32 AM

$NTLA Pre-announcement Friday after close and data pre-market on Monday with 38% short level? I’m in for a small trade here AH. Good luck to all and especially to long-term holders!

0 · Reply

burbs88 Apr. 25 at 8:24 AM

$CRSP $NTLA $PRME

0 · Reply

Monkey7779192 Apr. 25 at 5:20 AM

$NTLA This phase 3 readout not related to the one that got halted?

1 · Reply

Wischmop Apr. 25 at 3:56 AM

$NTLA A release on Monday morning? I don't think you need to be a rocket scientist to predict what will happen to the course...

1 · Reply

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Apr 3, 2026, 4:05 PM EDT - 21 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 3, 2026, 7:30 AM EST - 7 weeks ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 2, 2026, 10:05 AM EST - 7 weeks ago

Intellia Therapeutics Stock Gains — FDA Lifts Clinical Hold On Pivotal Trial

Mar 2, 2026, 7:40 AM EST - 7 weeks ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:30 AM EST - 7 weeks ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026, 7:30 AM EST - 2 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 24, 2026, 8:00 AM EST - 2 months ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

Feb 19, 2026, 7:30 AM EST - 2 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Jan 27, 2026, 1:03 PM EST - 3 months ago

Intellia Moves Forward As FDA Removes Trial Hold For Rare Disorder

Jan 27, 2026, 8:13 AM EST - 3 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 7, 2026, 7:30 AM EST - 3 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 26, 2025, 11:34 AM EST - 5 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

ATYR HIMS HTZ LCID REPL SOC WEN

Nov 10, 2025, 3:17 PM EST - 5 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 5 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Oct 29, 2025, 5:11 PM EDT - 6 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 7:38 AM EDT - 6 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 6 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Sep 25, 2025, 1:57 PM EDT - 7 months ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 9:52 AM EDT - 7 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 18, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 8 months ago

Why big players are pouring millions in THIS biotech stock

Aug 1, 2025, 7:30 AM EDT - 9 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 9 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 30, 2025, 11:07 AM EDT - 9 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

Jun 15, 2025, 10:45 AM EDT - 11 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

May 29, 2025, 11:25 AM EDT - 11 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 18, 2025, 7:25 AM EDT - 1 year ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 10, 2025, 10:40 AM EDT - 1 year ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 1 year ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 3, 2025, 1:03 PM EDT - 1 year ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

burbs88 Apr. 25 at 9:57 AM

$NTLA

0 · Reply

leon_dedrick Apr. 25 at 9:48 AM

$NTLA If these guys are successful Monday I think it will be more bullish for $EDIT thank any other company Why Just ask Google what licenses they hold!!!!

0 · Reply

burbs88 Apr. 25 at 9:47 AM

$CRSP $NTLA Biggest day in space Monday since Casgevy approval. The selling was just typical hedging ahead of super high risk event.

0 · Reply

janetgonzales54 Apr. 25 at 9:00 AM

$NTLA

0 · Reply

janetgonzales54 Apr. 25 at 8:36 AM

$NTLA

0 · Reply

Shirzo Apr. 25 at 8:33 AM

$CRSP move to $NTLA

0 · Reply

TKkamen Apr. 25 at 8:32 AM

$NTLA Pre-announcement Friday after close and data pre-market on Monday with 38% short level? I’m in for a small trade here AH. Good luck to all and especially to long-term holders!

0 · Reply

burbs88 Apr. 25 at 8:24 AM

$CRSP $NTLA $PRME

0 · Reply

Monkey7779192 Apr. 25 at 5:20 AM

$NTLA This phase 3 readout not related to the one that got halted?

1 · Reply

Wischmop Apr. 25 at 3:56 AM

$NTLA A release on Monday morning? I don't think you need to be a rocket scientist to predict what will happen to the course...

1 · Reply

WildFireWarrior Apr. 25 at 3:41 AM

MITQ 🚨Great setup into next week, keep eyes on this one 🚀 Low float + active news cycle + volume building = squeeze conditions forming. We’ve seen this movie before. Feels like news may be coming on MITQ: 🔹 Real hidden gem, has more revenue than market cap 🔹 Positioned in cinema digital transformation — software, audio/visual, and immersive experiences 🍿 🔹 History of sharp spikes — known for big moves when volume hits. $APE.X $ADTX $WYHG $NTLA ww/

1 · Reply

TrendyAce Apr. 25 at 3:28 AM

$NTLA decent day.

0 · Reply

WallStreetBuyDip Apr. 25 at 3:07 AM

$NTLA Trading at $13.63, with a wide price range between $6.87 and $27.98. Recent volume spiked to 7.8M but still higher than the average volume of 5.4M.

0 · Reply

RosemaryBarnett08 Apr. 25 at 3:04 AM

$CVKD Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events https://finance.yahoo.com/news/cvkd-phase-2-hit-results-113800506.html $NTLA $SOXX

1 · Reply

LQQKER_INSIDER Apr. 25 at 2:44 AM

$NTLA Hope I'm wrong. But I'm siding with the shorts (32.97%), and the big dumpers at EOD. Not betting on the after hour neophytes. 🍷💋

1 · Reply

jeojackson Apr. 25 at 2:11 AM

$NTLA Evidence of Significant Benefit? A trial may be stopped if interim data clearly shows that the new treatment is overwhelmingly effective. In such cases, it is considered unethical to continue giving the control group an inferior treatment when a superior option is already proven.

1 · Reply

jeojackson Apr. 25 at 2:09 AM

$NTLA Fk, I sold 50% of my NTLA holdings between 15 and 16. But got 25% back today. Hope it pans out.

0 · Reply

topstockalerts Apr. 25 at 1:46 AM

After Hours Top Gainers $DKI $ADTX $WYHG $NTLA $SLXN

0 · Reply

Evagaminska Apr. 25 at 12:41 AM

$NTLA I hope readouts will be great giving hope to patients and letting those that trusted the company and put their hard earned money buying the stock to profit. I don’t know what will MM crooks do but if you don’t want to risk it stock might run some more in pm $18 perhaps then we could see sell the news or bigger pump? No one knows Set your PT Good Luck to us

1 · Reply

Murphydingle Apr. 25 at 12:31 AM

$NTLA whats the bullshit

1 · Reply

BIOTECH_GURU Apr. 25 at 12:23 AM

$NTLA readout will be rock solid. Stock price movement will be harder to predict. W

0 · Reply

Oxinternet Apr. 25 at 12:10 AM

$NTLA I hope you all make shed loads of money on monday, but I’ve seen countless bio companies big up the news and it drops 30% even if they cure cancer, covid, parkinsons, flu and erectile disfunction in a single dose 🙄

0 · Reply

Market Cap	1.87B
Revenue (ttm)	67.67M
Net Income (ttm)	-412.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-609.86%
Debt to Equity Ratio	0.00

Volume	8,983,600
Avg Vol	3,566,912
Day's Range	N/A - N/A
Shares Out	118.13M
Stochastic %K	70%
Beta	1.99
Analysts	Sell
Price Target	$25.20